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ABSTRACT
In this study, 11 patients with solid tumors were ran-
domized to receive irinotecan (CPT-11; 200 mg/m2) as a
90-min i.v. infusion, immediately followed by cisplatin
(CDDP; 80 mg/m2) as a 3-h i.v. infusion in the first course
and the reversed sequence in the second course or vice versa.
No significant differences in any toxicity were observed
between the treatment schedules (decrease in absolute neu-
trophil count, 74.7 6 18.3 versus 80.3 6 18.0%; P 5 0.41).
CPT-11 lactone clearance was similar to single agent data
and not significantly different between study courses (60.4 6
17.1 versus 65.5 6 16.3 liter/h/m2; P 5 0.66). The kinetic
profiles of the major CPT-11 metabolites SN-38, SN-38 glu-
curonide, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piper-
idino]carbonyloxycamptothecine (APC), and 7-ethyl-10-[4-
N-(1-piperidino)-1-amino]carbonyloxycamptothecine (NPC)
were also sequence independent (P > 0.20). In addition,
CPT-11 had no influence on the clearance of nonprotein-
bound CDDP (40.8 6 16.7 versus 50.3 6 18.6 liter/h/m2; P 5
0.08) and the platinum DNA-adduct formation in peripheral
leukocytes in either sequence (1.94 6 2.20 versus 2.42 6 1.62
pg Pt/mg DNA; P 5 0.41). These data indicate that the
toxicity of the combination CPT-11 and CDDP is schedule
independent and that there is no mutual pharmacokinetic
interaction.
INTRODUCTION
Topoisomerase I inhibitors have demonstrated important
antitumor activity as single agents in various tumor types. Their
mechanism of action suggests that they might interfere in pro-
cesses involved in DNA repair and might enhance cytotoxicity
when combined with DNA-damaging agents. Interactions of
topoisomerase I inhibitors with platinum-derivatives have been
studied in vitro and in vivo, and the interaction observed for the
combination of CPT-112 and CDDP varied with the cell line
studied (1–4). Preclinical data also seemed to suggest the po-
tential of a sequence-dependent effect, with synergy increasing
when CDDP preceded CPT-11 incubation as compared with
concomitant exposure to both drugs in various cell lines (2).
However, the sequence-dependent cytotoxicity of the combina-
tion of topoisomerase I inhibitors and platinum-derivatives also
seemed to vary with the cell line studied and the schedule used
(1, 2).
In general, the design of effective combination chemother-
apy regimens requires adequate attention to possible drug inter-
actions at the pharmacokinetic and/or pharmacodynamic level.
Until now, the importance of drug sequencing for the combina-
tion of topoisomerase I inhibitors and platinum-derivatives has
clinically only been investigated for the combination of topote-
can and CDDP (5, 6). When CDDP was administered before a
5-day schedule of topotecan, significantly more and severe
hematological toxicity was encountered than with the alternate
sequence. Pharmacokinetic studies suggested that the differ-
ences in toxicity were due, in part, to a slower topotecan
clearance when CDDP preceded topotecan (5).
In all Phase I studies on the combination of CPT-11 and
CDDP, CPT-11 administration preceded that of CDDP (1,
7–13), and pharmacokinetic data were only scarcely obtained
(8). Against this background, we initiated a study in which
patients were treated in a randomized cross-over design to
determine whether the sequence of CPT-11 and CDDP admin-
istration has any influence on the observed toxicity or is related
to any pharmacokinetic interaction between the drugs.
MATERIALS AND METHODS
Eligibility Criteria. Patients with a histologically or cy-
tologically confirmed diagnosis of a malignant solid tumor
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refractory to standard forms of therapy were eligible. All
patients had adequate hematopoietic [absolute neutrophil
count ($2.0 3 109/liter) and platelet count ($100 3 109/
liter)], renal [serum creatinine concentration (#135 mmol/
liter) or creatinine clearance ($60 ml/min)], and hepatic
function [total serum bilirubin (#1.25 3 UNL) and serum
aspartate aminotransferase and alanine aminotransferase
(#3.0 3 UNL); in case of liver metastasis: total serum
bilirubin (#1.5 3 UNL) and serum aspartate aminotrans-
ferase and alanine aminotransferase (#5.0 3 UNL)]. All
patients gave written informed consent before study entry.
Treatment Plan and Drug Administration. Patients
were randomized to one of two treatment groups. In group A,
patients received CPT-11 as a 90-min i.v. infusion at a dose of
200 mg/m2 on day 1, immediately followed by the infusion of
CDDP at a dose of 80 mg/m2 as a 3-h i.v. infusion diluted in 250
ml of sodium chloride 3% (w/v) on day 1. Doses were selected
based on experience obtained in a preceding Phase I study.3 In
the second course, the sequence of administration of CPT-11
and CDDP was reversed, administering CDDP before CPT-11 at
the same doses. In case a patient encountered neutropenic fever
or grade 3 or 4 nonhematological toxicity (except nausea and
vomiting), the dose of CPT-11 was reduced to 175 mg/m2 and
CDDP was reduced to 60 mg/m2 in the second course. Group B
patients received the two treatment cycles in reverse order.
In all patients, premedication consisted of ondansetron (8
mg i.v.) combined with dexamethasone (10 mg i.v.) adminis-
tered 30 min before the start of the chemotherapy. The admin-
istration of chemotherapy was followed by infusion of 2000 ml
of dextrose/saline applied over 8 h and another 1000 ml of the
same solution infused over the following 8 h to avoid CDDP-
induced renal damage.
Pharmacokinetic Sampling and Analysis. Blood sam-
ples for pharmacokinetic analysis were obtained during the first
and second treatment cycle (total blood volume, 283 ml). Blood
was drawn from a vein in the arm opposite to that used for drug
infusion and collected in 10-ml heparinized tubes. For analysis
of CPT-11 kinetics, samples were obtained at the following time
points: before infusion; 0.5, 1, and 1.5 h during infusion; and
0.17, 0.33, 0.5, 1, 1.5, 2, 4, 5, 8.5, 11, 24, 32, 48, and 56 h after
infusion. Samples for measurement of CDDP concentrations
were obtained immediately before infusion; 1, 2, and 3 h during
infusion; and 0.5, 1, 2, 3, 4, and 24 h after infusion.
Plasma samples were assayed for total drug forms of
CPT-11 and metabolites and the lactone forms of CPT-11 and
SN-38, according to validated reversed-phase high performance
liquid chromatography methods reported previously (14, 15).
Nonprotein-bound and total CDDP concentrations in plasma
and platinum DNA-adduct levels in leukocytes were determined
by flameless atomic absorption spectrometry (16).
Individual plasma concentrations of CPT-11 and its me-
tabolites were fitted to a three-compartment model using
Siphar v4.0 (SIMED, Creteil, France), as described (17).
Metabolic ratios for the various CPT-11 metabolites were
calculated as defined by Rivory et al. (18) and included the
relative extent of conversion of CPT-11 to SN-38 (i.e.,
AUCSN-38/AUCCPT-11), the relative extent of glucuronidation
of SN-38 (i.e., AUCSN-38G/AUCSN-38), and the relative ex-
tent of metabolism (i.e., AUCAPC or NPC/AUCCPT-11). Kinetic
profiles of CDDP were obtained similarly using a one- or
two-compartment model with extended least-squares regres-
sion analysis, as reported earlier (16). The platinum DNA-
adduct levels in leukocytes were expressed as pg platinum/mg
DNA (pg Pt/mg DNA).
Statistical Considerations. Pharmacokinetic parameters
for all compounds are reported as mean values 6 SD. Differ-
ences in pharmacodynamic and pharmacokinetic parameters
between sequences were evaluated statistically using a paired
Student’s t test and the 95% confidence limits for the mean
difference using Number Cruncher Statistical System version
5.X (Dr. Jerry Hintze, Kaysville, UT) and STATGRAPHICS
Plus version 2.0 (Manugistics Inc., Rockville, MA). The power
to discern potentially clinically relevant differences in the test
parameters .30% (p) was determined at a 5 0.05 and previous
3 M. J. A. de Jonge, A. Sparreboom, A. S. T. Planting, M. E. L. van der
Burg, M. M. de Boer-Dennert, J. ter Steeg, C. Jacques, and J. Verweij.
Phase I study of 3-weekly irinotecan combined with cisplatin in patients
with advanced solid tumors. J. Clin. Oncol., in press, 1999.
Table 1 Summary of hematological pharmacodynamics
Data were obtained from patients after treatment with a 90-min i.v. infusion of CPT-11 at a dose level of 200 mg/m2 given either before
(CPT-113CDDP; first course) or after CDDP at a dose level of 80 mg/m2 (CDDP3CPT-11; second course) or vice versa. The relative hematological
toxicity (i.e., the percentage decrease in blood cell count) was defined as: %decrease 5 [(pretherapy value-nadir value)/(pretherapy value)] 3 100%.
Data represent mean values 6 SD.
Parameter CPT-113CDDP CDDP3CPT-11 CL (])a Pb
Leukocytes
Nadir (31029/liter) 2.54 6 1.15 2.23 6 1.29 21.70 and 1.08 0.50
%decrease WBC 65.7 6 20.9 69.6 6 18.1 219.6 and 27.5 0.61
Neutrophils
Nadir (31029/liter) 0.93 6 0.85 0.89 6 0.67 20.83 and 0.75 0.87
%decrease ANC 74.7 6 18.3 80.3 6 18.0 215.1 and 26.5 0.41
Platelets
Nadir (31029/liter) 219 6 57.6 198 6 61.2 247.8 and 7.0 0.09
%decrease PLC 34.3 6 18.8 38.8 6 25.4 218.5 and 27.5 0.55
a CL (]), 95% confidence limits for the mean difference; ANC, absolute neutrophil count; PLC, platelet count.
b Paired Student’s t test.
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pharmacological data (17).4 Probability values (two-sided) of
,0.05 were regarded as statistically significant.
RESULTS
Toxicity and Pharmacodynamics. A total of 11 pa-
tients, 6 males and 5 females with a median age of 59 years
(range, 41–66) and a median performance score of 1 (range,
0–1), was accrued to the study. However, one patient was taken
off study after receiving one course of chemotherapy because of
deterioration of his condition due to disease progression. The
predominant tumor type was colorectal cancer (n 5 7), and the
main toxicity consisted of neutropenia (grade 3 or 4 in both
sequences was observed in 6 of 10 cycles). Four patients en-
countered neutropenic fever (first course, n 5 2; second course,
n 5 2) in the sequence CDDP3CPT-11, and one patient (first
course only) in the sequence CPT-113 CDDP, which required
dose reductions for the second course in three cases
(CDDP3CPT-11, n 5 2; CPT-113CDDP, n 5 1). Hence,
only eight patients received the planned dose in the sequence
CPT-113CDDP, compared to nine patients in the reversed
sequence. Paired analysis of hematological pharmacodynamic
parameters indicated, however, that drug-sequencing had no
significant influence on the observed myelotoxicity (Table 1),
including the percent decrease in absolute neutrophil count (p 5
0.93). The severity and incidence of nonhematological toxici-
ties, including nausea [grade 2 or 3, n 5 4 (CPT-113CDDP)
versus n 5 4 (CDDP3CPT-11)], vomiting (grade 3 or 4, n 5
1 versus n 5 2), and diarrhea (grade 3 or 4, n 5 0 versus n 5
1), were also sequence independent.
Pharmacokinetics. The pharmacokinetics of CPT-11
and its metabolites SN-38, SN-38G, APC, and NPC could best
be described by a three-compartmental model (Fig. 1A), in line
with previous findings (17). Elimination of CPT-11 was char-
acterized by a decay in an apparent tri-exponential manner and
indicated no significant difference between sequences (Table 2).
Analysis of the 10 paired, dose-normalized AUCs of CPT-11
lactone in both sequences demonstrated also no significant
differences, indicating that treatment with CDDP immediately
before CPT-11 did not alter the clearance of CPT-11 lactone
(p 5 0.99). The AUC ratios of CPT-11 lactone to total drug
were 0.37 6 0.07 and 0.35 6 0.14, whereas for SN-38 these
were 0.67 6 0.15 and 0.62 6 0.27, in the sequences CPT-
113CDDP and CDDP3 CPT-11, respectively (Table 3).
The mean values for the apparent terminal half-lives of
SN-38 and SN-38G, APC and NPC were similar in both se-
quences of drug administration (Table 3). In addition, the rela-
tive extent of conversion of CPT-11 to SN-38 was not influ-
enced by the administration sequence (0.047 6 0.018 versus
0.046 6 0.027, P 5 0.92), and neither was the relative extent of
glucuronidation of SN-38 (9.12 6 5.22 versus 9.01 6 6.99, P 5
0.87). No sequence dependence was observed in the metabolism
of CPT-11 to APC and NPC, as estimated from the relative
extent of oxidative metabolism [APC: 0.23 6 0.10 versus
0.23 6 0.08 (P 5 0.77); NPC: 0.012 6 0.011 versus 0.011 6
0.009 (P 5 0.14)].
CDDP pharmacokinetics could best be described with a
two-compartment model (Fig. 1B), as described (16). The total
body clearance and the Vss of unbound CDDP were the same in
both sequences (p 5 0.64), indicating no influence of the drug
sequence on the protein binding of CDDP (Table 4). The plat-
inum-DNA adduct levels in leukocytes peaked consistently at
1 h after the end of infusion, and showed wide interpatient
variability (Table 4). Administration of CPT-11 before CDDP
resulted in a mean value of 1.94 6 2.20 pg Pt/mg DNA that was
comparable with 2.42 6 1.62 pg Pt/mg DNA observed in the
reverse sequence (P 5 0.41).
DISCUSSION
This study was performed to explore the influence of
alternate sequences of CPT-11 and CDDP on the observed side
effects and pharmacokinetic behavior of both drugs. Using a
randomized cross-over design for the administration sequence,
no substantial differences in any toxicity were observed between
the two treatment schedules. The pharmacokinetics of the lac-
4 M. J. A. de Jonge, J. Verweij, P. de Bruijn, E. Brouwer, R. H. J.
Mathijssen, R. J. van Alphen, L. Vernillet, C. Jacques, and A. Sparre-
boom. Pharmacokinetic, metabolic and pharmacodynamic profiles in a
dose escalating study of irinotecan and cisplatin. J. Clin. Oncol., in
press, 1999.
Fig. 1 Plasma concentration-time curves of CPT-11 lactone (A) and
unbound CDDP (B) in 10 patients given CPT-11 before (F) or after
CDDP (E). Data represent mean values (symbols) 6 SD (bars).
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tone form of CPT-11 revealed a substantial degree of interpa-
tient variability, in line with previous observations (17). In
addition, the observed kinetic parameters of CPT-11 were sim-
ilar to single agent data (18), indicating no apparent interaction
between CDDP and CPT-11. The sequence of drug administra-
tion had also no influence on the pharmacokinetics of CPT-11
and its metabolites SN-38 and SN-38G and the CYP450 3A4-
mediated metabolites APC and NPC at the dose levels admin-
istered. This contrasts the reduction of topotecan clearance
observed previously in patients after CDDP administration (5).
Our findings, however, are consistent with previous in vitro
studies, indicating that CDDP had no statistically significant
effect on the carboxylesterase-mediated bioactivation of
CPT-11 to SN-38 using human hepatic microsomes (19). In that
study, there was also a lack of protein-binding site displacement
of CPT-11 by CDDP in a clinically relevant concentration range
(19).
The total body clearance and Vss of unbound CDDP, as
well as the plasma AUC of total CDDP, indicated no significant
influence of CPT-11 (or its metabolites) on the protein binding
and plasma disposition of CDDP. The values of the maximal
platinum DNA-adduct formation in peripheral leukocytes and
the area under the DNA-adduct versus time curve were consist-
ent with single-agent data (16) and were independent of the drug
sequence. In preclinical studies, however, topoisomerase I in-
hibitors delayed the repair of platinum-induced DNA interstrand
cross-links without modifying their formation (1). Although
there is no formal proof that this preclinical observation also
Table 2 Summary of dose-normalized pharmacokinetic parameters of CPT-11 lactone
Data were obtained from 10 cancer patients after treatment with a 90-min i.v. infusion of CPT-11 at a dose level of 200 mg/m2 given either before
(CPT-113CDDP; first course) or after CDDP at a dose level of 80 mg/m2 (CDDP3CPT-11; second course) or vice versa. In three second courses,
the CPT-11 and CDDP doses were reduced to 175 mg/m2 and 60 mg/m2, respectively, due to severe toxicity encountered in the first course
(CPT-113CDDP, n 5 1; CDDP3CPT-11, n 5 2). All parameters were calculated by compartmental analysis, and data represent dose-normalized
(to 200 mg/m2) mean values 6 SD.
Parameter CPT-113CDDP CDDP3CPT-11 CL (])a P
Cmax (mM) 1.89 6 0.393 1.74 6 0.449 20.55 and 0.34 0.60
t1/2(a) (h) 0.180 6 0.146 0.167 6 0.097 20.17 and 0.13 0.79
t1/2(b) (h) 1.70 6 0.81 1.98 6 0.85 20.46 and 1.03 0.87
t1/2(g) (h) 12.2 6 2.85 12.3 6 2.63 22.08 and 2.48 0.85
AUC (mMzh) 6.13 6 2.07 5.58 6 1.86 21.01 and 0.87 0.89
CL (liter/h/m2) 60.4 6 17.1 65.5 6 16.3 29.31 and 13.9 0.66
MRT (h) 7.98 6 2.07 7.46 6 1.53 21.43 and 1.05 0.74
Vss (liter/m2) 477 6 131 483 6 166 2279 and 121 0.39
a CL (]), 95% confidence limits for the mean difference; Cmax, maximum concentration; t1/2(i), half-life of the i-th disposition phase; CL, total
body clearance; MRT, mean residence time.
b Paired Student’s t test.
Table 3 Summary of dose-normalized pharmacokinetic parameters of total CPT-11 and metabolites (lactone plus carboxylate forms)
Data were obtained from 10 cancer patients after treatment with a 90-min i.v. infusion of CPT-11 at a dose level of 200 mg/m2 given either before
(CPT-113CDDP; first course) or after CDDP at a dose level of 80 mg/m2 (CDDP3CPT-11; second course) or vice versa. In three second courses,
the CPT-11 and CDDP doses were reduced to 175 mg/m2 and 60 mg/m2, respectively, due to severe toxicity encountered in the first course
(CPT-113CDDP, n 5 1; CDDP3CPT-11, n 5 2). All parameters were calculated by compartmental analysis, and data represent dose-normalized
(to 200 mg/m2) mean values 6 SD.
Parameter CPT-113CDDP CDDP3CPT-11 CL (])a Pb
CPT-11
t1/2 (h) 12.9 6 3.52 11.4 6 2.27 24.22 and 1.03 0.25
AUC (mMzh) 16.6 6 6.52 17.3 6 8.66 21.36 and 2.16 0.20
AUCL/AUCT 0.37 6 0.07 0.35 6 0.14 20.094 and 0.076 0.62
SN-38
t1/2 (h) 25.5 6 7.6 21.9 6 3.9 24.09 and 0.95 0.81
AUC (mMzh) 0.30 6 0.17 0.29 6 0.14 20.23 and 0.19 0.19
AUCL/AUCT 0.67 6 0.15 0.62 6 0.27 20.017 and 0.019 0.84
SN-38G
t1/2 (h) 21.4 6 6.19 22.7 6 3.71 23.20 and 5.78 0.88
AUC (mMzh) 5.39 6 3.60 5.50 6 3.50 22.32 and 2.56 0.53
APC
t1/2 (h) 10.1 6 4.17 9.05 6 2.60 23.35 and 1.29 0.23
AUC (mMzh) 3.91 6 2.73 4.04 6 2.48 20.81 and 1.06 0.34
NPC
t1/2 (h) 5.32 6 2.86 6.05 6 3.64 21.52 and 3.65 0.75
AUC (mMzh) 0.32 6 0.37 0.22 6 0.23 20.24 and 0.043 0.35
a CL (]), 95% confidence limits for the mean difference; t1/2, half-life of the terminal disposition phase; AUCL, AUC of the lactone form; AUCT,
AUC of total drug.
b Paired Student’s t test.
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applies to the clinical situation, it is possible that the small
patient population studied, in combination with the extreme
variability in platinum DNA-adduct values, would not allow any
alteration to be observed even if it were present.
In our study, CDDP was immediately administered at the
end of the CPT-11 infusion, or vice versa in the alternate
sequence. The lack of sequence dependence in the kinetic pro-
files of both drugs in this schedule does not necessarily indicate
that any reciprocal pharmacokinetic interference will be absent
when the administration interval is increased. In this respect, it
is noteworthy that CDDP can modulate specific CYP450
mRNA levels and may alter hepatic drug metabolism in vivo
(20), a mechanism that has recently been proposed to account
for drug interactions between CDDP and paclitaxel (21) or
CDDP and etoposide (22). In view of the major role of CYP450
isozymes in CPT-11 metabolism and disposition (17), drug
interactions with CDDP cannot be excluded a priori in case of
alternative schedules of administration.
In conclusion, no sequence-dependent side effects between
CPT-11 and CDDP could be demonstrated in this study, nor an
indication of a mutual pharmacokinetic interaction. On the basis
of these findings and the conflicting data on the mechanism of
drug interaction between topoisomerase I inhibitors and plati-
num derivatives in preclinical models, no clear preference in
administration sequence can yet be formulated.
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(to 80 mg/m2) mean values 6 SD.
Parameter CPT-113CDDP CDDP3CPT-11 CL (])a Pb
Cmax (mg/ml) 0.84 6 0.30 0.77 6 0.25 21.03 and 1.17 0.36
t1/2 (h) 0.73 6 0.23 0.49 6 0.15 20.62 and 1.10 0.074
AUCfu (mgzh/ml) 2.35 6 0.83 2.01 6 0.66 20.25 and 0.95 0.10
AUCtot (mgzh/ml) 39.8 6 12.9 35.8 6 6.4 21.84 and 9.96 0.58
CL (liter/h/m2) 40.8 6 16.7 50.3 6 18.6 220.2 and 1.05 0.081
Vss (liter/m2) 35.5 6 14.3 30.0 6 11.6 20.47 and 11.5 0.083
Amax (pg Pt/mg DNA) 1.94 6 2.20 2.42 6 1.62 21.55 and 0.59 0.41
a CL (]), 95% confidence limits for the mean difference; Cmax, maximum concentration; t1/2(el), half-life of the terminal disposition phase;
AUCfu, AUC of unbound CDDP; AUCtot, AUC of total CDDP; CL, total body clearance; Amax, maximum CDDP DNA-adduct level in leukocytes.
b Paired Student’s t test.
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